Sol-Gel Technologies Ltd. (SLGL): Total Assets
$29.92M
As of 2025-12-31
-13.8%
3-year compound annual growth
-12.7%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $29.92M | -16.5% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $35.85M | -20.8% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $45.29M | -2.9% | 2025-04-29, Balance as of period end |
| 2022-12-31 | $46.63M | -32.6% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $69.19M | +17.0% | 2023-03-10, Balance as of period end |
| 2020-12-31 | $59.16M | -3.5% | 2022-04-07, Balance as of period end |
| 2019-12-31 | $61.30M | -12.0% | 2021-03-04, Balance as of period end |
| 2018-12-31 | $69.68M | +355.0% | 2020-03-24, Balance as of period end |
| 2017-12-31 | $15.31M | +39.4% | 2019-03-21, Balance as of period end |
| 2016-12-31 | $10.98M | n/a | 2018-03-26, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $29.92M | -16.5% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $20.27M | -14.8% |
| Scynexis Inc (SCYX) | 2025-12-31 | $59.03M | -34.9% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $25.65M | -52.2% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $769.28M | -11.0% |
| uniQure N.V. (QURE) | 2025-12-31 | $824.91M | +48.2% |
| Alumis Inc. (ALMS) | 2025-12-31 | $411.94M | +20.8% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $377.38M | -28.3% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $50.24M | +36.3% |
Compare SLGL, EVFM, SCYX, CASIF side by side · Screen every company in Pharmaceutical Preparations ↗